These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31587697)

  • 21. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
    Peltzer J; Aletti M; Frescaline N; Busson E; Lataillade JJ; Martinaud C
    Front Immunol; 2018; 9():2013. PubMed ID: 30271402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic sclerosis: Recent insights.
    Elhai M; Avouac J; Kahan A; Allanore Y
    Joint Bone Spine; 2015 May; 82(3):148-53. PubMed ID: 25557659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic sclerosis: a prototypic multisystem fibrotic disorder.
    Varga J; Abraham D
    J Clin Invest; 2007 Mar; 117(3):557-67. PubMed ID: 17332883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.
    Pattanaik D; Postlethwaite AE
    Discov Med; 2010 Aug; 10(51):161-7. PubMed ID: 20807477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
    Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
    PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis.
    Corallo C; Franci B; Lucani B; Montella A; Chirico C; Gonnelli S; Nuti R; Giordano N
    Int J Immunopathol Pharmacol; 2015 Mar; 28(1):93-103. PubMed ID: 25816411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systemic sclerosis and macrovascular involvement: Status of the issue in 2019].
    Bertolino J; Scafi M; Benyamine A; Aissi K; Boufi M; Schleinitz N; Sarlon G; Rossi P; Granel B
    J Med Vasc; 2019 Dec; 44(6):400-421. PubMed ID: 31761307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of systemic sclerosis-current concept and emerging treatments.
    Furue M; Mitoma C; Mitoma H; Tsuji G; Chiba T; Nakahara T; Uchi H; Kadono T
    Immunol Res; 2017 Aug; 65(4):790-797. PubMed ID: 28488090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of systemic sclerosis (scleroderma).
    Rosendahl AH; Schönborn K; Krieg T
    Kaohsiung J Med Sci; 2022 Mar; 38(3):187-195. PubMed ID: 35234358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic sclerosis-scleroderma.
    Haustein UF
    Dermatol Online J; 2002 Jun; 8(1):3. PubMed ID: 12165213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scleroderma - new aspects in pathogenesis and treatment.
    Balbir-Gurman A; Braun-Moscovici Y
    Best Pract Res Clin Rheumatol; 2012 Feb; 26(1):13-24. PubMed ID: 22424190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Vessels Contribute to Fibrosis in Systemic Sclerosis.
    Di Benedetto P; Ruscitti P; Liakouli V; Cipriani P; Giacomelli R
    Isr Med Assoc J; 2019 Jul; 21(7):471-474. PubMed ID: 31507123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis.
    Hasegawa M; Sato S
    Front Biosci; 2008 May; 13():3637-47. PubMed ID: 18508461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One year in review 2016: systemic sclerosis.
    Barsotti S; Stagnaro C; d'Ascanio A; Della Rossa A
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):3-13. PubMed ID: 27463613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.